[1]
|
Sadykova, L.R., Ntekim, A.I., Muyangwa-Semenova, M., Rutland, C.S., Jeyapalan, J.N., Blatt, N. and Rizvanov, A.A. (2020) Epidemiology and Risk Factors of Osteosarcoma. Cancer Investigation, 38, 259-269.
https://doi.org/10.1080/07357907.2020.1768401
|
[2]
|
Mirabello, L., Troisi, R.J. and Savage, S.A. (2009) Interna-tional Osteosarcoma Incidence Patterns in Children and Adolescents, Middle Ages and Elderly Persons. International Journal of Cancer, 125, 229-234.
https://doi.org/10.1002/ijc.24320
|
[3]
|
Odri, G.A., Tchicaya-Bouanga, J., Yoon, D.J.Y. and Modrowski, D. (2022) Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers. Cancers, 14, Article 360.
https://doi.org/10.3390/cancers14020360
|
[4]
|
Hattinger, C.M., Patrizio, M.P., Fantoni, L., Casotti, C., Riganti, C. and Serra, M. (2021) Drug Resistance in Osteosarcoma: Emerging Biomarkers, Therapeutic Targets and Treatment Strategies. Cancers, 13, Article 2878.
https://doi.org/10.3390/cancers13122878
|
[5]
|
Mirabello, L., Troisi, R.J. and Savage, S.A. (2009) Osteosarcoma Incidence and Survival Rates from 1973 to 2004: Data from the Surveillance, Epidemiology, and End Results Program. Cancer, 115, 1531-1543.
https://doi.org/10.1002/cncr.24121
|
[6]
|
Beird, H.C., Bielack, S.S., Flanagan, A.M., Gill, J., Heymann, D., Jane-way, K.A., Livingston, J.A. and Roberts, R.D., Strauss, S.J. and Gorlick, R. (2022) Osteosarcoma. Nature Reviews Disease Primers, 8, Article No. 77.
https://doi.org/10.1038/s41572-022-00409-y
|
[7]
|
Iasonos, A., Schrag, D., Raj, G.V. and Panageas, K.S. (2008) How to Build and Interpret a Nomogram for Cancer Prognosis. Journal of Clinical Oncology, 26, 1364-1370. https://doi.org/10.1200/JCO.2007.12.9791
|
[8]
|
Danieli, M. and Gronchi, A. (2023) Staging Systems and Nomo-grams for Soft Tissue Sarcoma. Current Oncology, 30, 3648-3671. https://doi.org/10.3390/curroncol30040278
|
[9]
|
Bakhshi, S. and Radhakrishnan, V. (2010) Prognostic Markers in Osteosarcoma. Expert Review of Anticancer Therapy, 10, 271-287. https://doi.org/10.1586/era.09.186
|
[10]
|
李明, 裴晓宁, 岳恺, 等. 血清指标对骨肉瘤化疗预后判别价值[J]. 中国矫形外科杂志, 2020, 28(19): 1770-1774.
|
[11]
|
田聪, 王炯轶, 刘峰, 等. 合并病理性骨折对肢体骨肉瘤患者预后影响的Meta分析[J]. 肿瘤, 2015, 35(3): 312-321.
|
[12]
|
流小舟, 周幸, 周光新, 等. 266例四肢骨肉瘤患者的临床疗效分析[J]. 医学研究生学报, 2021, 34(4): 365-370.
https://doi.org/10.16571/j.cnki.1008-8199.2021.04.006
|
[13]
|
Wu, X., Wang, J. and He, D. (2023) Establishment and Validation of a Competitive Risk Model for Predicting Cancer-Specific Survival in Patients with Osteosarcoma: A Population-Based Study. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-023-05320-x
|
[14]
|
Mahaffey, K.W., Granger, C.B., Sloan, M.A., Thompson, T.D., Gore, J.M., Weaver, W.D., White, H.D., Simoons, M.L., Barbash, G.I., Topol, E.J. and Califf, R.M. (1998) Risk Factors for in-Hospital Nonhemorrhagic Stroke in Patients with Acute Myocardial Infarction Treated with Thrombolysis: Results from GUSTO-I. Circulation, 97, 757-764.
https://doi.org/10.1161/01.CIR.97.8.757
|
[15]
|
Finnell, D.L., Davis, G.A., Cropp, C.D. and Ensom, M.H. (1998) Validation of the Hartford Nomogram in Trauma Surgery Patients. Annals of Pharmacotherapy, 32, 417-421. https://doi.org/10.1345/aph.17243
|
[16]
|
Balachandran, V.P., Gonen, M., Smith, J.J. and DeMatteo, R.P. (2015) Nomograms in Oncology: More than Meets the Eye. The Lancet Oncology, 16, E173-E180. https://doi.org/10.1016/S1470-2045(14)71116-7
|
[17]
|
Puppo, P. and Perachino, M. (1997) Clinical Stage, Pros-tate-Specific Antigen and Gleason Grade to Predict Extracapsular Disease or Nodal Metastasis in Men with Newly Di-agnosed, Previously Untreated Prostate Cancer. European Urology, 32, 273-279. https://doi.org/10.1159/000480824
|
[18]
|
Wu, H., Xu, G., Li, Z., Xu, Y., Lin, Y., Chekhonin, V.P., Peltzer, K., Wang, J., Li, S., Li, H., Zhang, J., Xue, Y., Ma, W., Wang, X. and Zhang, C. (2022) Nomogram Predicting Leukopenia in Osteosarcoma after High-Dose Methotrexate Chemotherapy. Aging, 14, 5023-5033. https://doi.org/10.18632/aging.203978
|
[19]
|
Zhang, L., Ge, Y., Gao, Q., Zhao, F., Cheng, T., Li, H. and Xi,a Y. (2021) Machine Learning-Based Radiomics Nomogram with Dynamic Contrast-Enhanced MRI of the Osteosarcoma for Evaluation of Efficacy of Neoadjuvant Chemotherapy. Frontiers in Oncology, 11, Article 758921. https://doi.org/10.3389/fonc.2021.758921
|
[20]
|
Zhong, J., Zhang, C., Hu, Y., Zhang, J., Liu, Y., Si, L., Xing, Y., Ding, D., Geng, J., Jiao, Q., Zhang, H., Yang, G. and Yao, W. (2022) Automated Prediction of the Neoadjuvant Chem-otherapy Response in Osteosarcoma with Deep Learning and an MRI-Based Radiomics Nomogram. European Radiolo-gy, 32, 6196-6206.
https://doi.org/10.1007/s00330-022-08735-1
|
[21]
|
Lin, P., Yang, P.F., Chen, S., Shao, Y.Y., Xu, L., Wu, Y., Teng, W., Zhou, X.Z., Li, B.H., Luo, C., Xu, L.M., Huang, M., Niu, T.Y. and Ye, Z.M. (2020) A Delta-Radiomics Model for Preoperative Evaluation of Neoadjuvant Chemotherapy Response in High-Grade Osteosarcoma. Cancer Imaging, 20, Article No. 7.
https://doi.org/10.1186/s40644-019-0283-8
|
[22]
|
Zheng, S., Chen, L., Wang, J., Wang, H., Hu, Z., Li, W., Xu, C., Ma, M., Wang, B., Huang, Y., Liu, Q., Tang, Z.R., Liu, G., Wang, T., Li, W. and Yin, C. (2023) A Clinical Prediction Model for Lung Metastasis Risk in Osteosarcoma: A Multicenter Retrospective Study. Frontiers in Oncology, 13, Article 1001219.
https://doi.org/10.3389/fonc.2023.1001219
|
[23]
|
Li, W., Dong, S., Wang, B., Wang, H., Xu, C., Zhang, K., Li, W., Hu, Z., Li, X., Liu, Q., Wu, R. and Yin, C. (2022) The Construction and Development of a Clinical Prediction Model to Assess Lymph Node Metastases in Osteosarcoma. Frontiers in Public Health, 9, Article 813625. https://doi.org/10.3389/fpubh.2021.813625
|
[24]
|
Shao, Z., Li, J., Liu, Z. and Bi, S. (2023) Establishment and Vali-dation of Systematic Prognostic Nomograms in Patients over 60 Years of Age with Osteosarcoma: A Multicenter Exter-nal Verification Study. Cancer Medicine, 12, 9589-9603.
https://doi.org/10.1002/cam4.5736
|
[25]
|
Li, W., Jin, G., Wu, H., Wu, R., Xu, C., Wang, B., Liu, Q., Hu, Z., Wang, H., Dong, S., Tang, Z.R., Peng, H., Zhao, W. and Yin, C. (2022) Interpretable Clinical Visualization Model for Predic-tion of Prognosis in Osteosarcoma: A Large Cohort Data Study. Frontiers in Oncology, 12, Article 945362. https://doi.org/10.3389/fonc.2022.945362
|
[26]
|
Gao, B., Wang, M.D., Li, Y. and Huang, F. (2022) Risk Stratifica-tion System and Web-Based Nomogram Constructed for Predicting the Overall Survival of Primary Osteosarcoma Pa-tients after Surgical Resection. Frontiers in Public Health, 10, Article 949500. https://doi.org/10.3389/fpubh.2022.949500
|
[27]
|
Yang, Q.K., Lai, Q.Y., Wang, Y., Wang, Y., Yao, Z.X. and Zhang, X.J. (2021) Establishment and Validation of Prognostic Nomograms to Predict Overall Survival and Can-cer-Specific Survival for Patients with Osteosarcoma. Neoplasma, 68, 434-446. https://doi.org/10.4149/neo_2020_200617N639
|
[28]
|
Han, T., Wu, Z., Zhang, Z., Liang, J., Xia, C. and Yan, H. (2023) Comprehensive Analysis of Hypoxia-Related Genes for Prognosis Value, Immune Status, and Therapy in Osteo-sarcoma Patients. Frontiers in Pharmacology, 13, Article 1088732. https://doi.org/10.3389/fphar.2022.1088732
|
[29]
|
Meng, J., Du, H., Lu, J. and Wang, H. (2023) Construction and Validation of a Predictive Nomogram for Ferroptosis-Related Genes in Osteosarcoma. Journal of Cancer Research and Clinical Oncology, 149, 14227-14239.
https://doi.org/10.1007/s00432-023-05225-9
|
[30]
|
Jin, Z., Wu, J., Lin, J., Wang, J. and Shen, Y. (2022) Identifica-tion of the Transcription Co-Factor-Related Gene Signature and Risk Score Model for Osteosarcoma. Frontiers in Ge-netics, 13, Article 862803.
https://doi.org/10.3389/fgene.2022.862803
|
[31]
|
Wang, X., Lu, J., Song, Z., Zhou, Y., Liu, T. and Zhang, D. (2022) From Past to Future: Bibliometric Analysis of Global Research Productivity on Nomogram (2000-2021). Frontiers in Public Health, 10, Article 997713.
https://doi.org/10.3389/fpubh.2022.997713
|